In 4 SLE patients who had improved SLEDAI-2K scores and renal SLEDAI-2K scores after treatment, the frequency of CD226+ B cells decreased after medication (Figures 3A–C, shown in solid lines). This evidence concerns the gene CD226 and systemic lupus erythematosus.